Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic cancer patients treated with chemoradiotherapy.

Date publication

février 2025

Journal

European journal of clinical nutrition

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Perrier M, Fontaine M, Bertin E, Carlier C, Botsen D, Djelouah M, François E, Guilbert P, Saint A, Slimano F, Torielli P, Brugel M, Bouché O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39910182

Résumé

Low skeletal muscle mass and impaired muscle quality (myosteatosis) have been associated with poor outcomes in cancer patients. This study aimed to evaluate the impact of pre-therapeutic low muscle mass and myosteatosis on chemoradiotherapy (CRT)-induced toxicity and survival outcomes in patients with non-resectable pancreatic cancer (PC).

Référence

Eur J Clin Nutr. 2025 02 5;: